A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma

• Main Authors: Zhong, L, Fu, X.-Y, Zou, C, Yang, L.-L, Zhou, S, Yang, J, Tang, Y, Cheng, C, Li, L.-L, Xiang, R, Chen, L.-J, Chen, Y.-Z, Wei, Y.-Q, Yang, S.-Y
• Other Authors: PHARMACY
• Format: Article
• Published: Wiley-Liss Inc. 2020
• Subjects: 1-(4-((1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea; angiogenesis inhibitor; antineoplastic agent; carbanilamide derivative; nicotinamide; protein kinase inhibitor; pyrazole derivative; sorafenib; analogs and derivatives; animal; Bagg albino mouse; cancer transplantation; Carcinoma, Hepatocellular; cell motion; cell proliferation; cell survival; chemistry; cytology; drug screening; endothelium cell; female; human; IC50; liver; Liver Neoplasms; metabolism; mouse; neovascularization (pathology); signal transduction; tumor cell line; umbilical vein endothelial cell; zebra fish; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Liver; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Zebrafish
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/180162
• Institution: National University of Singapore

10.1002/ijc.28944